Sichuan Hebang Biotechnology Co., Ltd.

Sichuan Hebang Biotechnology Co., Ltd. experienced notable stock volatility on March 20, 2026, with a significant decline. Despite recent challenges, including a drop in net profit and negative results over ten quarters, the company has shown positive year-to-date and annual performance metrics, alongside a low debt-to-equity ratio.

Sichuan Hebang Biotechnology Co., Ltd. saw its stock drop significantly today, contrasting with the broader market's performance. Despite a recent monthly increase, the company has faced profitability challenges, with a notable decline in net profit and sales in the first half of the year, raising concerns about its financial health.

Sichuan Hebang Biotechnology Co., Ltd. saw a decline in its stock today, contrasting with a slight gain in the China Shanghai Composite. Despite a significant monthly increase, the company has faced ongoing financial challenges, reporting negative results for ten consecutive quarters, while maintaining a market capitalization of CNY 21,018 million.

Sichuan Hebang Biotechnology Co., Ltd. saw a decline in its stock today, contrasting with the minor decrease in the China Shanghai Composite. Despite recent gains, the company faces challenges with declining net sales and profits, having reported negative results for the last ten quarters amid a significant annual increase.

Sichuan Hebang Biotechnology Co., Ltd. saw a notable increase in its stock price on March 12, 2026, reaching an intraday high. Over the past week, the stock has risen significantly, outperforming the China Shanghai Composite. However, the company faces challenges, including declining net profit and negative results over recent quarters.

Sichuan Hebang Biotechnology Co., Ltd. has experienced notable short-term stock gains, contrasting with the broader market. However, the company faces long-term challenges, including stagnant net sales growth and declining operating profit. Despite a significant annual return, profits have sharply decreased, highlighting a complex financial situation.

Sichuan Hebang Biotechnology Co., Ltd. has seen significant stock performance, with notable increases over the past month and year-to-date. Despite these gains, the company faces challenges, including declining net and operating profits over the last five years, and has reported negative results for ten consecutive quarters.

Sichuan Hebang Biotechnology Co., Ltd. faced a significant stock decline on March 3, 2026, despite a strong monthly performance and substantial annual returns. The company has struggled with declining net sales and negative results over ten quarters, prompting concerns about its long-term growth and financial health.

Sichuan Hebang Biotechnology Co., Ltd. saw a notable rise in its stock today, contrasting with a decline in the broader market. The company has shown strong weekly and monthly gains, but faces long-term challenges, including declining operating profits and negative results over the past ten quarters.

Sichuan Hebang Biotechnology Co., Ltd. saw a notable increase in its stock performance on February 24, 2026, achieving an intraday high of CNY 2.62. The company has shown significant growth over the past week and month, although it faces long-term challenges, including declining net profit. Its market capitalization is CNY 21,018 million.